UBS AM’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

UBS AM’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,820	Closed	-$80.9K	–	2763
2022 Q3	$80.9K	Sell	3,820 -1,350	-26%	-$36.4K	﹤0.01%	2704
2022 Q2	$125K	Hold	5,170	–	–	﹤0.01%	2625
2022 Q1	$257K	Hold	5,170	–	–	﹤0.01%	2630
2021 Q4	$363K	Hold	5,170	–	–	﹤0.01%	2642
2021 Q3	$482K	Hold	5,170	–	–	﹤0.01%	2521
2021 Q2	$520K	Buy	5,170 +85	+2%	+$8.29K	﹤0.01%	2523
2021 Q1	$474K	Sell	5,085 -7	-0.1%	-$710	﹤0.01%	2411
2020 Q4	$420K	Buy	+5,092	New	+$434K	﹤0.01%	2346

Other funds holding VBIV

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

UBS AM's VBIV Position: Q4 2022 in Review

UBS AM sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q4 2022, closing a stake of 3,820 shares — an estimated $80.9K sold.

UBS AM first reported a position in VBIV in Q4 2020 and held it in 8 quarters. The position peaked at $520K in Q2 2021. 111 funds tracked by Wall St. Rank hold VBIV as of Q4 2022.

UBS AM reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q4 2022 after selling out during the quarter.
UBS AM sold 3,820 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q4 2022, an estimated $80.9K.
UBS AM first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2020 and held it in 8 quarters.
UBS AM's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $520K in Q2 2021.
111 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q4 2022.

Based on UBS AM's 13F filing for Q4 2022, filed 14 Feb 2023.